Carol Suh

Carol Suh has a diverse work experience in various roles and industries. Carol started their career as a Consultant/Intern at ARCH Venture Partners in February 2018, before progressing to the position of Senior Associate in August 2018 and eventually becoming a Principal in August 2019. In July 2021, they were promoted to the role of Partner, which they currently hold.

In 2019, Carol co-founded Neumora and served as the Co-founder and VP of Business Development until December 2021. Carol then took on the roles of Co-founder and SVP of Strategy from January 2022 to March 2023 and is currently the Co-founder and Chief Operating Officer.

Carol also co-founded Orbital Therapeutics in March 2022 and serves as a Board Member. In addition, Carol serves as a Board Member for HIBio and is the Board Member of Metrodora Foundation at Metrodora Institute.

Prior to their ventures, Carol worked at Boundless Bio as an Associate Director of Corporate Development from May 2019 to December 2019. Carol also gained experience at Magenta Therapeutics as a Business Development and Corporate Strategy Associate and Launch Fellow from May 2016 to September 2017.

Before entering the biotech and venture capital industries, Carol worked as a Senior Associate Consultant at Trinity Partners from January 2015 to May 2016. Carol also worked at GlaxoSmithKline as an R&D Strategy and Innovation Fellow from May 2014 to December 2014.

Carol Suh has a Bachelor of Arts (B.A.) degree in Molecular and Cellular Biology from Harvard University. Carol also holds a Master of Philosophy (M.Phil.) degree in Genetics from Yale University. Additionally, Carol has attended Stanford University Graduate School of Business, although the specific details such as start and end years are not provided. Here, they pursued a Master of Business Administration (MBA) degree.